Top News

Merck Announces $1.35 Billion Acquisition of Imago BioSciences

November 28, 2022

Merck will purchase Imago BioSciences, a biotechnology company focused on bone marrow disorders, for approximately $1.35 billion.

Regeneron and Cytomx Announce $2 Billion Oncology Collaboration

November 22, 2022

The collaboration will see the companies develop investigational next-generation bispecific immunotherapies for cancer.

Sanofi and Insilico Medicine Ink $1.2 Billion Drug Development Deal

November 16, 2022

The deal will see Sanofi use Insilico’s AI drug discovery platform to advance up to six new drug development candidates.

J&J to Acquire Abiomed for $16.6 Billion

November 02, 2022

Johnson & Johnson’s acquisition of Abiomed, a provider of heart pump technologies, is designed to bolster their position in the medical technology sector.

CPHI 2022 Award Winners Announced

November 02, 2022

The winners of the 2022 CPHI Excellence in Pharma Awards were announced on Nov. 1, 2022 at an awards ceremony in Frankfurt, Germany.

Gilead and MacroGenics Enter $1.7 Billion Oncology Collaboration

October 19, 2022

Gilead and MacroGenics will work together on bispecific antibodies for the treatment of blood cancers.

Merck and Moderna Enter $250 Million Cancer Vaccine Partnership

October 14, 2022

Merck has exercised a $250 million option with Moderna to jointly develop and commercialize cancer vaccine mRNA-4157/V940.

FDA Authorizes Bivalent COVID-19 Boosters for Children Ages Five and Older

October 13, 2022

FDA amended its authorization for the Moderna and Pfizer-BioNTech bivalent booster vaccines to permit their use in children as young as five years old.

Biogen to Settle Kickbacks Lawsuit for $900 Million

September 28, 2022

Biogen has agreed to pay $900 million to settle federal and state claims that it paid kickbacks to physicians to encourage them to prescribe its drugs.

Pfizer to Supply up to 6 Million PAXLOVID Treatment Courses for Low-and-Middle-Income Countries

September 27, 2022

Pfizer is set to supply global fund up to 6 million treatment courses of its COVID-19 oral treatment, PAXLOVID, for low-and-middle-income countries.